Lurline
  • Seen : 770 View

0
Lurline

Lorelene is a slow-release injectable containing loperurine acetate, an LHRH analogue that is secreted from the hypothalamus. Lorelene is a slow-release injectable form of lupivrelin acetate, which uses micro-oncapsulation modulation curves and induces continuous drug release for 6 weeks of effective suppression of testosterone after a monthly subcutaneous injection. A single-dose vial containing 2.5 or 2.5 mg of leuprolide, 3.5 or 65.64 mg of l-lactic acid and glycolic acid copolymer (equal to each), and 2.5 or 2.5 mg. Gram is di-mannitol. The ampoule contains 5 ml of solvent to make the suspension.

Indications
-Prostate Cancer
Endometriosis
Pre-menopausal breast cancer
- Nuclear myoma progression and improvement of symptoms of uterine myoma with hypermenorrhea, hypogastric pain, back pain and anemia
- Central early maturity

Saler Company Information

Company : Teda
Phone : 00982177654216
More Information : View
Online order registration form
No comments have been posted yet
loading
Your comment has been sent
Lurline

Lorelene is a slow-release injectable containing loperurine acetate, an LHRH analogue that is secreted from the hypothalamus. Lorelene is a slow-release injectable form of lupivrelin acetate, which uses micro-oncapsulation modulation curves and induces continuous drug release for 6 weeks of effective suppression of testosterone after a monthly subcutaneous injection. A single-dose vial containing 2.5 or 2.5 mg of leuprolide, 3.5 or 65.64 mg of l-lactic acid and glycolic acid copolymer (equal to each), and 2.5 or 2.5 mg. Gram is di-mannitol. The ampoule contains 5 ml of solvent to make the suspension.

Indications
-Prostate Cancer
Endometriosis
Pre-menopausal breast cancer
- Nuclear myoma progression and improvement of symptoms of uterine myoma with hypermenorrhea, hypogastric pain, back pain and anemia
- Central early maturity

Saler Company Information

Company : Teda
Phone : 00982177654216
More Information : View
Online order registration form